Novartis, announced data from the 52-week pivotal phase III PALLADIUM clinical trial which demonstrated that QMF149, a once-daily fixed-dose combination of indacaterol acetate and mometasone furoate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback